Topics

Glioblastoma | Treatment | Clinical trials | Bevacizumab and other angiogenesis inhibitors

Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Bevacizumab

Tanaka T, Tamura R, Takei J, Morimoto Y, Teshigawara A, Yamamoto Y, Imai R, Kuranari Y, Tohmoto K, Hasegawa Y, Akasaki Y, Murayama Y, Miyake K, Sasaki H.
An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma.
J Neurooncol. 2024 Jan 31. doi: 10.1007/s11060-023-04544-8. PMID: 38291182. Interventional study. ˍ

Motamed-Sanaye A, Mortezaei A, Afshari AR, Saadatian Z, Faraji AH, Sheehan JP, Mokhtari AM.
Angiogenesis inhibitors effects on overall survival and progression-free survival in newly diagnosed primary glioblastoma multiforme: a meta-analysis of twelve randomized clinical trials.
J Neurooncol. 2024 Dec 5. doi: 10.1007/s11060-024-04865-2. PMID: 39636552. Meta-analysis˰ ˍ

Chen KT, Tsai HC, Huang CY, Liau CT, Ho KC, Toh CH, Chuang CC, Hsu PW, Huang YC, Chang TW, Yeap MC, Chen PY, Lee CC, Lin YJ, Feng LY, Airan RD, Li G, Lim M, Liu HL, Wei KC.
Combination of Neuronavigation-Guided Focused Ultrasound and Bevacizumab for Patients With Recurrent Glioblastoma: A Pilot Study.
Neurosurgery. 2025 Nov 24. doi: 10.1227/neu.0000000000003851. PMID: 41283685. Interventional study. ˍ